OncoMyx Therapeutics, a Phoenix, AZ-based oncolytic immunotherapy company, completed a $25m series A financing.
The round was led by Boehringer Ingelheim Venture Fund (BIVF), Delos Capital, and Xeraya Capital with participation from Korea Investment Partners (KIP), City Hill Ventures, and Madison Partners.
Concurrent with the financing, Steve Potts, Ph.D., MBA, founder and chief executive officer of OncoMyx, Kanad Das, Ph.D., representing BIVF, Tim Xiao, CFA, FRM, representing Delos Capital, Jason Rushton, representing Xeraya Capital, and Grant McFadden, Ph.D., founder and research advisor, have joined OncoMyx’s board of directors.
OncoMyx Therapeutics develops oncolytic immunotherapies based on the myxoma virus (MYXV) platform from Arizona State University (ASU) to orchestrate an immune response and treat cancer.
The company plans to use the funds to advance development of its lead oncolytic virus (OV) therapeutic program for the treatment of various cancers.